Aptose Biosciences Inc.

Posters & Presentations

All Poster Presentation
March 17, 2020 Presentation

Aptose Biosciences Inc Corporate Presentation March 2020

Aptose Biosciences Inc Corporate Presentation March 2020: View Presentation
February 11, 2020 Presentation

Aptose Biosciences Inc. at BIO CEO 2020 Conference Presentation

Aptose Biosciences Inc. at BIO CEO 2020 Conference Presentation: View Presentation
February 5, 2020 Presentation

Key Opinion Leader Symposium: CG-806 for AML

Key Opinion Leader Symposium: CG-806 for AML: View Presentation
January 13, 2020 Presentation

Aptose Biosciences Inc. at Biotech Showcase™ 2020 Conference Presentation

Aptose Biosciences Inc. at Biotech Showcase™ 2020 Conference Presentation: View Presentation
December 9, 2019 Poster

2019 ASH Poster - Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

2019 ASH Poster - Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas: View Poster
December 8, 2019 Poster

2019 ASH Poster - CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

2019 ASH Poster - CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells: View Poster
December 7, 2019 Presentation

Aptose Corporate Update at ASH 2019: Early Clinical Observations with CG-806 and APTO-253

Aptose Corporate Update at ASH 2019: Early Clinical Observations with CG-806 and APTO-253: View Presentation
October 24, 2019 Poster

2019 ESH Poster - CG-806 Pan-FLT3/Pan-BTK Inhibitor Simultaneously Suppresses Multiple Oncogenic Signaling Pathways to Treat AML

2019 ESH Poster - CG-806 Pan-FLT3/Pan-BTK Inhibitor Simultaneously Suppresses Multiple Oncogenic Signaling Pathways to Treat AML: View Poster
June 14, 2019 Poster

2019 EHA Poster - CG-806, PRECLINICAL IN VIVO EFFICACY AND SAFETY PROFILE AS A PAN-FLT3 / PAN-BTK INHIBITOR

2019 EHA Poster - CG-806, PRECLINICAL IN VIVO EFFICACY AND SAFETY PROFILE AS A PAN-FLT3 / PAN-BTK INHIBITOR: View Poster